Positive Phase III data inspires $133M Eurand IPO - FierceBiotech

Positive Phase III data inspires $133M Eurand IPO - FierceBiotech: "Eurand has filed for an IPO of seven million shares designed to raise up to $133 million. The drug developer, which has operations in Europe as well as the U.S., plans to sell its shares for $17 to $19 each. The offering is following closely on the heels of an announcement in early April that its lead therapy delivered positive results in two late-stage studies. "